Pemetrexed (Alimta)

First FDA Approved Treatment for Mesothelioma in 15 Years

In the Fall of 2018 scientists and researchers from Novocure, an oncology company that specializes in treating solid tumors, were hopeful their latest success with Tumor Treating Fields therapy would lead to FDA approval and ultimately, more options for those suffering from mesothelioma. After a successful clinical trial, these hopes[…]

Read More »

Currently Recruiting: Mesothelioma Clinical Trials

When it comes to effective mesothelioma treatments, options are unfortunately limited. There is no cure for mesothelioma and first line chemotherapy treatment Alimta, is no guarantee.  Many who are suffering from mesothelioma, who have found little or no comfort in traditional treatments, may turn to clinical trials for hope.  Through[…]

Read More »

Survival Factors for Mesothelioma Highlighted by University of Pittsburgh Medical Center

According to GLOBOCAN 2018 statistics, each year there are 30,443 mesothelioma cases worldwide, and of those 30,443, 25,576 pass away.  With close to 85 percent of those diagnosed succumbing to the disease, mesothelioma remains one of the most deadly cancers as there is no cure. However, surviving a mesothelioma diagnosis[…]

Read More »

UK Pharmaceutical Company’s Potential Cancer Vaccine Assists in Treating Mesothelioma

Combination treatment therapies are common for those suffering from mesothelioma because the aggressive nature of this asbestos-caused disease makes it difficult to treat effectively.  Ongoing developments and advancements in medicine have also helped mesothelioma patients extend their life and manage pain throughout the years. While there is no cure for[…]

Read More »

Phase III Clinical Trial for Nintedanib Discontinued After Yielding Negative Results

Disappointing results from the LUME-Phase III clinical trial regarding nintedanib is a setback for scientists and researchers who were hopeful they were on the brink of finding a new, first line treatment for those suffering from mesothelioma. Results from the Phase II clinical trial – published earlier this year –[…]

Read More »

Why is Chemotherapy Often Ineffective in Those Suffering from Mesothelioma?

Mesothelioma is a difficult cancer to treat for a multitude of reasons. A mesothelioma diagnosis is rare – only about 3,000 people per year in the United States are diagnosed – and this can make it difficult to study, given that there is generally a very small sample of patients[…]

Read More »

ONCOS-102 Update: Mesothelioma Patients Responded after Phase II Clinical Trial

Advancement in mesothelioma treatments over the past decade has been relativity stagnant, according to Targovax  – a Norwegian immune-cology company dedicated to the study and research of immunotherapy treatments. However, those suffering from mesothelioma have hope, as continuing phases of clinical trials are showing positive results; the latest being ONCOS-12,[…]

Read More »

Immunotherapy Treatment Durvalumab Enters Phase II Clinical Trial

While there is no cure for mesothelioma, those who are able to withstand surgery in general may have a better chance of survival, as the cancer is being physically removed. However, mesothelioma is a difficult cancer and often surgery is not an option, and the cancer is unresectable. The success[…]

Read More »

Effective Chemotherapy May Rest Upon Reducing Overactive Enzyme

Chemotherapy for mesothelioma patients has been notoriously difficult and the cancer continues to be overwhelmingly unresponsive to such treatment in many cases. However, researchers and scientists have been continually investigating new techniques that involve adjusting how chemotherapy reacts on a cellular level. A study published in the Frontiers in Pharmacology[…]

Read More »

ONCOS-102 Passes Safety Evaluation in Phase I Clinical Trials, Phase II Clinical Trial Recommended

A new immunotherapy developed by Targovax has recently passed Phase I clinical trials and is set to begin Phase II evaluation of this new treatment that may help those suffering from mesothelioma. ONCOS-102 was used in separate Phase I clinical trials; one in combination with chemotherapy, and one with immunotherapy.[…]

Read More »